Xuebijing Injection Show Promise in Reducing Mortality Rates for Sepsis Patients

Professor Qiu Haibo and his research team from the Intensive Care Unit (ICU) at Zhongda Hospital, Affiliated Hospital of Southeast University, confirmed that a traditional Chinese medicine injection can reduce the 28-day all-cause mortality rate in sepsis patients and have reliable clinical safety. The research findings were recently published in the journal "JAMA Internal Medicine."

The study included 1817 patients diagnosed with sepsis (Sepsis-3), who were randomly assigned in a 1:1 ratio to receive Xuebijing or a placebo intravenously. The primary endpoint was the 28-day all-cause mortality rate after randomization. The results showed that the Xuebijing group had a lower 28-day all-cause mortality rate than the placebo group (7.3% vs. 26.1%; 95% CI, 3.4% - 11.2%), P<0.001. Furthermore, the Xuebijing group had a 5.8% lower ICU mortality rate, 5.8% lower hospital mortality rate, 2.1 additional ICU-free days, and 1.8 additional days without mechanical ventilation within 28 days.

The study confirmed that intravenous administration of Xuebijing at a dose of 100 mL every 12 hours for five consecutive days in early-stage sepsis patients can reduce the 28-day all-cause mortality rate with reliable clinical safety. Safety analysis showed a total of 422 adverse events (25.3% in the placebo group, 22.9% in the Xuebijing group), indicating similar safety profiles between the two groups.

Xuebijing injection is composed of safflower, red peony, chuanxiong, salvia miltiorrhiza, and angelica sinensis, which can promote the elimination of inflammatory factors. It is mainly used to treat critically ill patients with sepsis or organ dysfunction associated with inflammatory storms. Since its market launch in 2004, Xuebijing injection has been extensively studied through evidence-based medicine research for clinical effectiveness and safety in the field of critical illness, involving multiple disciplines such as respiratory, emergency, and intensive care medicine. During the COVID-19 pandemic, Xuebijing has played a significant role in treatment in China.

Chase Sun Pharma aims to accelerate the integration of digital applications with its six major business sectors. Leveraging the latest scientific research achievements and the advantages of its multi-industry chain layout, Chase Sun will further promote the revitalization and development of traditional Chinese medicine, benefiting billions of people with high-quality traditional Chinese medicine and services.